Home > Insider Trading > Filing (0001209191-20-037076)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649094	Vaxcyte Inc.	PCVX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1365617	J Patrick Heron	C/O Vaxcyte, Inc. 353 Hatch Drive Foster City CA 94404		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-06-16	1,692,494	$0.00	1,692,494	No	4	C	Indirect	By Frazier Life Sciences VIII, L.P.
Common Stock	Acquisiton	2020-06-16	226,236	$0.00	1,918,730	No	4	C	Indirect	By Frazier Life Sciences VIII, L.P.
Common Stock	Acquisiton	2020-06-16	140,824	$0.00	2,059,554	No	4	C	Indirect	By Frazier Life Sciences VIII, L.P.
Common Stock	Acquisiton	2020-06-16	250,000	$16.00	2,309,554	No	4	P	Indirect	By Frazier Life Sciences VIII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Frazier Life Sciences VIII, L.P.
No	4	C	Indirect	By Frazier Life Sciences VIII, L.P.
No	4	C	Indirect	By Frazier Life Sciences VIII, L.P.
No	4	P	Indirect	By Frazier Life Sciences VIII, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-06-16	1,692,494	$0.00	1,692,494	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-06-16	226,236	$0.00	226,236	$0.00
Common Stock	Series D Preferred Stock	Disposition	2020-06-16	140,824	$0.00	140,824	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series B Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date.
The shares are held of record by Frazier Life Sciences VIII, L.P. ("FLS VIII"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS VIII and FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. Patrick Heron and James Topper may be deemed to beneficially own the shares which are held by FLS VIII as they are the sole managing members of FHM LLC and therefore share voting and dispositive power over the shares held by FLS VIII. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date.
The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date.